Groesbeck Investment Management Corp NJ Sells 260 Shares of ICON Public Limited (NASDAQ:ICLR)

Groesbeck Investment Management Corp NJ cut its holdings in ICON Public Limited (NASDAQ:ICLR) by 12.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,911 shares of the medical research company’s stock after selling 260 shares during the period. Groesbeck Investment Management Corp NJ’s holdings in ICON Public were worth $401,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Park Place Capital Corp lifted its position in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares during the last quarter. GAMMA Investing LLC lifted its position in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the last quarter. First Horizon Advisors Inc. lifted its position in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its position in ICON Public by 76.0% during the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock worth $187,000 after acquiring an additional 386 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on ICLR shares. Evercore ISI reduced their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. TD Cowen reduced their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. The Goldman Sachs Group reduced their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Redburn Atlantic initiated coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price for the company. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $285.75.

ICON Public Stock Down 1.1 %

ICON Public stock opened at $193.27 on Wednesday. The company has a market cap of $15.94 billion, a P/E ratio of 21.55, a price-to-earnings-growth ratio of 1.79 and a beta of 1.19. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a fifty day simple moving average of $208.53 and a 200 day simple moving average of $256.54. ICON Public Limited has a 1-year low of $183.38 and a 1-year high of $347.72.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.